secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001193125-23-297169
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru prices public offering of 45.8M shares at $0.72, net proceeds ~$35.2M for enobosarm trial
--------------------------------------------------------------------------------

- Entered underwriting agreement for 45,833,333 shares at $0.72/share; gross proceeds ~$33M.
- Underwriters' option for 6,874,999 additional shares exercised in full on Dec 15.
- Net proceeds expected ~$35.2M after discounts and expenses.
- Proceeds primarily fund Phase 2b trial of enobosarm for muscle preservation in obese elderly on GLP-1 agonists.
- Offering expected to close Dec 18, 2023; Raymond James and Oppenheimer lead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523297169/0001193125-23-297169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523297169/d584595d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-297169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer